1355324-97-8

Basic information

• Product Name: 2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(o-tolyl)ethyl)-N-(3-fluorophenyl)acetamide
• Synonyms: 2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(o-tolyl)ethyl)-N-(3-fluorophenyl)acetamide
• CAS NO: 1355324-97-8
• Molecular Weight: 416.923
• Mol File: 1355324-97-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(o-tolyl)ethyl)-N-(3-fluorophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(o-tolyl)ethyl)-N-(3-fluorophenyl)acetamide(1355324-97-8)
• EPA Substance Registry System: 2-chloro-N-(2-(cyclohexylamino)-2-oxo-1-(o-tolyl)ethyl)-N-(3-fluorophenyl)acetamide(1355324-97-8)

Safety Data

• Hazardous Substances Data: 1355324-97-8(Hazardous Substances Data)

Upstream product

• 372-19-0 meta-fluoroaniline 
• 931-53-3 Cyclohexyl isocyanide 
• 79-11-8 chloroacetic acid 
• 529-20-4 2-methylphenyl aldehyde 

Downstream Products

• 1355325-47-1 C₃₂H₃₆FN₃O₂ 
• 1355327-12-6 C₃₀H₃₄FN₃O₂ 
• 1355327-15-9 C₂₉H₃₀F₂N₂O₃ 
• 1355327-07-9 C₃₁H₃₄FN₃O₃ 
• 1355326-84-9 C₂₈H₃₀F₂N₄O₂ 
• 1355326-35-0 AGI-5198 
• 1355326-85-0 N-cyclohexyl-2-(N-(3-fluorophenyl)-2-((6-fluoropyridin-3-yl)amino)acetamido)-2-(o-tolyl)acetamide 

Relevant articles and documents

Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction

Isocitrate dehydrogenases 1 (IDH1) catalyzes the oxidative decarboxylation of isocitrate to ɑ-ketoglutaric acid (α-KG). It is the most frequently mutated metabolic gene in human cancer and its mutations interfere with cell metabolism and epigenetic regulation, thus promoting tumorigenesis. In order to discover potent new mutant IDH1 inhibitors, based on the structure of marketed inhibitor AG-120 (Ivosidenib), we designed, synthesized and evaluated a series of linear unnatural peptide analogues via Ugi reaction, as potential mutant IDH1 inhibitors. All these compounds were evaluated for their inhibition on mutant IDH1 enzyme activity. The structure-activity relationship was discussed on the basis of experimental data, with an attempt to pave the way for future studies. Among them, 43 exhibited potent and selective enzyme inhibitory activity, and showed strong binding affinity with mutant IDH1. It can decrease the cellular concentration of 2-HG, and suppress the proliferation of HT1080 and IDH1 mutant-U-87 cells by selectively inhibiting the activity of mutant IDH1.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1 comprising administering to a subject in need thereof a compound described here.